Cognito Therapeutics and West Virginia University Rockefeller Neuroscience Institute launch new care model to treat Alzheimer ...
In August 2024, LEQEMBI was approved for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback